Top

Journal of Cancer Survivorship

Published in:

05-12-2022 | Breast Cancer

Subjective cancer-related cognitive impairments and salience network connectivity in breast cancer survivors

Authors: Ashley M. Henneghan, Shelli R. Kesler

Published in: Journal of Cancer Survivorship | Issue 4/2023

Abstract

Purpose

Little is known about the neural basis of subjective cancer-related cognitive changes. The purpose of this study was to explore salience network connectivity in relation to subjective executive and memory dysfunction in breast cancer survivors compared to controls.

Methods

A retrospective cross-sectional analysis of neuroimaging, subjective cognitive, clinical, and demographic data in chemotherapy-treated primary breast cancer survivors compared to frequency matched controls was used. Functional connectivity within salience network hubs (anterior cingulate, bilateral insula) was determined using resting state functional MRI. Mann–Whitney U tests were used to evaluate group differences and Spearman’s rho correlations were examined among the behavioral measures and salience network connectivity.

Results

We included 65 breast cancer survivors and 71 controls. Survivors demonstrated greater subjective executive dysfunction and memory complaints (p < .001) and lower salience network connectivity (p < .05) than controls. Executive functioning correlated with bilateral insula and left anterior cingulate connectivity (rho > − 0.29, p < .05). Distress did not correlate with salience network connectivity.

Conclusion

These findings suggest that salience network connectivity may represent a biomarker of subjective cancer-related cognitive changes.

Implications for Cancer Survivors

Subjective cancer-related cognitive changes are common following treatment and associated with objective changes in brain connectivity

Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter MB, Castel H. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40.PubMedCrossRef

Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One. 2014;9(9):e108002.PubMedPubMedCentralCrossRef

Porro B, Durand MJ, Petit A, Bertin M, Roquelaure Y. Return to work of breast cancer survivors: toward an integrative and transactional conceptual model. J Cancer Surviv. 2021;16(3):590–603.PubMedPubMedCentralCrossRef

Mayo SJ, Lustberg M, Dhillon HM, Nakamura ZM, Allen DH, Von ah D, Janelsins MC, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D’Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer. 2021;29(6):2821–40.PubMedCrossRef

Bray VJ, Dhillon HM, Vardy JL. Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv. 2018;12(4):537–59.PubMedCrossRef

Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–34.PubMedCrossRef

Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin. 2015;65(2):123–38.PubMedCrossRef

Kaiser J, Bledowski C, Dietrich J. Neural correlates of chemotherapy-related cognitive impairment. Cortex. 2014;54:33–50.PubMedCrossRef

Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J. Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev. 2013;37(8):1311–21.PubMedCrossRef

10.

Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G, Dhabhar FS. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.PubMedCrossRef

11.

Kesler SR. Prevalence of cerebral small-vessel disease in long-term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. Breast Diseases: A Year Book Quarterly. 2015;26(4):353.

12.

Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J. 2008;14(6):396–400.PubMedCrossRef

13.

Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.PubMedCrossRef

14.

Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431–8.PubMedPubMedCentralCrossRef

15.

Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res. 2009;151:387–419.PubMedCrossRef

16.

Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.PubMedCrossRef

17.

Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104(10):2222–33.PubMedCrossRef

18.

McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.PubMedCrossRef

19.

Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447–53.PubMedPubMedCentralCrossRef

20.

Askren MK, Jung M, Berman MG, Zhang M, Therrien B, Peltier S, Ossher L, Hayes DF, Reuter-Lorenz PA, Cimprich B. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat. 2014;147(2):445–55.PubMedPubMedCentralCrossRef

21.

Apple AC, Schroeder MP, Ryals AJ, Wagner LI, Cella D, Shih PA, Reilly J, Penedo FJ, Voss JL, Wang L. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. NeuroImage Clin. 2018;20:110–8.PubMedPubMedCentralCrossRef

22.

S.R. Kesler, T. Tang, A.M. Henneghan, M. Wright, M.W. Gaber, O. Palesh, Cross-sectional characterization of local brain network connectivity pre and post breast cancer treatment and distinct association with subjective cognitive and psychological function, Frontiers in neurology 12(1969) (2021).

23.

Kesler SR, Wefel JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci USA. 2013;110(28):11600–5.PubMedPubMedCentralCrossRef

24.

Dumas JA, Makarewicz J, Schaubhut GJ, Devins R, Albert K, Dittus K, Newhouse PA. Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study. Brain Imaging Behav. 2013;7(4):524–32.PubMedCrossRef

25.

Zeng Y, Cheng ASK, Song T, Sheng X, Zhang Y, Liu X, Chan CCH. Subjective cognitive impairment and brain structural networks in Chinese gynaecological cancer survivors compared with age-matched controls: a cross-sectional study. BMC Cancer. 2017;17(1):796.PubMedPubMedCentralCrossRef

26.

Chand GB, Wu J, Hajjar I, Qiu D. Interactions of the salience network and its subsystems with the default-mode and the central-executive networks in normal aging and mild cognitive impairment. Brain Connectivity. 2017;7(7):401–12.PubMedPubMedCentralCrossRef

27.

Seeley WW. The salience network: a neural system for perceiving and responding to homeostatic demands. J Neurosci. 2019;39(50):9878–82.PubMedPubMedCentralCrossRef

28.

Chong JSX, Ng GJP, Lee SC, Zhou J. Salience network connectivity in the insula is associated with individual differences in interoceptive accuracy. Brain Struct Funct. 2017;222(4):1635–44.PubMedCrossRef

29.

Roth RM, Lance CE, Isquith PK, Fischer AS, Giancola PR. Confirmatory factor analysis of the behavior rating inventory of executive function-adult version in healthy adults and application to attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2013;28(5):425–34.PubMedPubMedCentralCrossRef

30.

Troyer AK, Rich JB. Psychometric Properties of a New Metamemory Questionnaire for Older Adults. J Gerontol B Psychol Sci Soc Sci. 2002;57(1):P19–27.PubMedCrossRef

31.

AAghakhani EK Chan Test Reviews: Bracken BA, Howell K 2004. Clinical Assessment of Depression Odessa, FL: Psychological Assessment Resources. J Psychoeduc Assess. 2007;25(4):416–22. CrossRef

32.

Glover GH, Lai S. Self-navigated spiral fMRI: interleaved versus single-shot. Magn Reson Med. 1998;39(3):361–8.PubMedCrossRef

33.

Ashburner J. SPM: a history. Neuroimage. 2012;62(2):791–800.PubMedCrossRef

34.

Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connectivity. 2012;2(3):125–41.PubMedCrossRef

35.

Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007;37(1):90–101.PubMedCrossRef

36.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15(1):273–89.PubMedCrossRef

37.

Van der Gucht K, Ahmadoun S, Melis M, de Cloe E, Sleurs C, Radwan A, Blommaert J, Takano K, Vandenbulcke M, Wildiers H, Neven P, Kuppens P, Raes F, Smeets A, Sunaert S, Deprez S. Effects of a mindfulness-based intervention on cancer-related cognitive impairment: results of a randomized controlled functional magnetic resonance imaging pilot study. Cancer. 2020;126(18):4246–55.PubMedCrossRef

38.

R.M. Roth, P.K. Isquith, G. Gioia, Behavioral rating inventory of executive function - adult version, Psychological Assessment Resources, Lutz, FL, 2005.

39.

Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacol. 2022;47(1):72–89.CrossRef

40.

Menon V, D’Esposito M. The role of PFC networks in cognitive control and executive function. Neuropsychopharmacol. 2022;47(1):90–103.CrossRef

41.

Bernstein LJ, Edelstein K, Sharma A, Alain C. Chemo-brain: an activation likelihood estimation meta-analysis of functional magnetic resonance imaging studies. Neurosci Biobehav Rev. 2021;130:314–25.PubMedCrossRef

42.

Gratton C, Sun H, Petersen SE. Control networks and hubs. Psychophysiol. 2018;55(3):e13032.

43.

Hou J, Song B, Chen ACN, Sun C, Zhou J, Zhu H, Beauchaine TP. Review on neural correlates of emotion regulation and music: implications for emotion dysregulation. Front Psychol. 2017;8:501.PubMedPubMedCentralCrossRef

44.

Conley CC, Bishop BT, Andersen BL. Emotions and emotion regulation in breast cancer survivorship. Healthcare (Basel). 2016;4(3):56.PubMedCrossRef

45.

Arndt J, Das E, Schagen SB, Reid-Arndt SA, Cameron LD, Ahles TA. Broadening the cancer and cognition landscape: the role of self-regulatory challenges. Psychooncol. 2014;23(1):1–8.CrossRef

46.

Flavell JH. Metacognition and cognitive monitoring: a new area of cognitive-developmental inquiry. Am Psychol. 1979;34(10):906–11.CrossRef

47.

Vaccaro AG, Fleming SM. Thinking about thinking: a coordinate-based meta-analysis of neuroimaging studies of metacognitive judgements. Brain Neurosci Adv. 2018;2:2398212818810591.PubMedPubMedCentralCrossRef

48.

Perrier J, Joue G, Desgranges B, Allouache D, Levy C, Noal S, Dayan J, Eustache F, Joly F, Viard A, Giffard B. Self-referential processes and resting-state connectivity in breast cancer patients before and 1 year after chemotherapy. Eur J Neurosci. 2022;55(2):624–36.PubMedCrossRef

49.

Sha Z, Wager TD, Mechelli A, He Y. Common dysfunction of large-scale neurocognitive networks across psychiatric disorders. Biol Psychiatry. 2019;85(5):379–88.PubMedCrossRef

50.

Kesler SR, Wayfull JS, Hosseini SM, Cheung M, Watson CL, Hoeft F. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci USA. 2013;110(28):11600–5. PubMedPubMedCentralCrossRef

51.

Sharma N, Murari G, Vandermorris S, Verhoeff N, Herrmann N, Chen JJ, Mah L. Functional connectivity between the posterior default mode network and parahippocampal gyrus is disrupted in older adults with subjective cognitive decline and correlates with subjective memory ability. J Alzheimer’s Disease : JAD. 2021;82(1):435–45.PubMedCrossRef

52.

Costa DSJ, Fardell JE. Why are objective and perceived cognitive function weakly correlated in patients with cancer? J Clin Oncol. 2019;37(14):1154–8.PubMedCrossRef

53.

Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102–13.PubMedPubMedCentralCrossRef

Title: Subjective cancer-related cognitive impairments and salience network connectivity in breast cancer survivors
Authors: Ashley M. Henneghan
Shelli R. Kesler
Publication date: 05-12-2022
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Journal of Cancer Survivorship / Issue 4/2023
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-022-01307-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 4/2023

The utility of surveillance CT scans in a cohort of survivors of colorectal cancer

Social adjustment across the lifespan in survivors of pediatric acute lymphoblastic leukemia (ALL): a systematic review

Childhood lymphoma treatment impacts educational outcomes: a registry study from Sweden

Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data

Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire

Associations between perceptions of relationship quality and markers of inflammation and insulin resistance among couples coping with cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer